Start Date
December 31, 2011
Primary Completion Date
February 29, 2012
Study Completion Date
February 29, 2012
SOM230
60 mg intramuscularly (IM) on day 1 of each 28 day cycle
Bortezomib
1.3 mg/m2 intravenously (IV) on days 1, 4, 8, and 11 of each cycle. Bortezomib will be infused by IV push.
Dexamethasone
20 mg orally on day of and day after bortezomib (Days 1, 2, 4, 5, 8, 9, 11, 12).
Hillman Cancer Center, Pittsburgh
Collaborators (1)
Novartis
INDUSTRY
University of Pittsburgh
OTHER